With Mirati embroiled in a management overhaul Amgen moves to consolidate its upper hand.
But competition in obesity is looming.
The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
What goes down must come up.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.